$ABEO News

Abeona’s (ABEO) Gene Therapy Launch Hits A Pivotal Reimbursement Milestone

Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlights: ZEVASKYN Revenue Surges 31% ...

ABEO: Zevaskyn® Launch Gains Momentum

Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21

Abeona Therapeutics Inc. Q2 2026 Earnings Call Summary

Abeona Therapeutics: Earnings Sell-Off Could Be A Buy Opportunity

Abeona Therapeutics Q2 Earnings Call Highlights

Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript

Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update

Abeona Therapeutics Q2 2026 Earnings Call Transcript

Abeona Therapeutics Q2 EPS $(0.35) Misses $(0.23) Estimate, Sales $11.380M Miss $12.239M Estimate

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®

Abeona Therapeutics Says CMS Granted New Technology Add-On Payment Status For ZEVASKYN Under Fiscal Year 2027 Hospital Inpatient Prospective Payment System Final Rule

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

Abeona Therapeutics Activates Cincinnati Children’s As Seventh Qualified Treatment Center For Administration Of ZEVASKYN To Treat Wounds In Patients With Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

ABEO: Three Patients Treated in 1Q26 with Two Additional QTCs Activated